Roche News & Brews

Roche seeks to highlight major developments across therapeutic categories and technology platforms. Within the Oncology space Roche PHCS is excited to present updates with FOLR1 and HER2 Low. Beyond Oncology, Roche PHCS is excited to share updates in Multiplex, Digital Pathology, and to highlight our new mass spectrometry unit and assay menu. Roche will also share updates on the Neuro Toolkit, NASH and Sepsis.

Oncology update:
• FOLR1 - Roche PHCS is giving hope to women by identifying patients with platinum resistant ovarian cancer who currently have no available treatments
• HER2-Low - Roche PHCS has worked with pharmaceutical partners to develop a new scoring algorithm enabling hundreds of thousands of women to access breast cancer treatment

Other technology areas:
• Multiplex - Roche PHCS is looking for partnering to develop CDx assays
• Digital Pathology - Roche PHCS open collaboration model continues to make strong progress as indicated by recent announcements of third parties in the industry
• Mass spectrometry - seamless integration into cobas pro integrated solutions as well as an IVD assay menu of more than 60 assays in 2 launch waves

Other therapeutic areas:
• Neuro Tool Kit - for our partners, this is access to robust prototype assays with a highly reliable technology which enables generation and comparison of high-quality
clinical biomarker data
• NASH & Sepsis - our solutions transform the patient journey in the areas with the most burning unmet medical needs